Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 15;49(2):306-9.
doi: 10.1086/600044.

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings

N Kumarasamy  1 , Vidya Madhavan, Kartik K Venkatesh, S Saravanan, Rami Kantor, P Balakrishnan, Bella Devaleenal, S Poongulali, Tokugha Yepthomi, Suniti Solomon, Kenneth H Mayer, Constance Benson, Robert Schooley
Affiliations

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings

N Kumarasamy et al. Clin Infect Dis. .

Abstract

Continuation of failed highly active antiretroviral therapy regimens can lead to the accumulation of mutations that may limit options for second-line treatment. We studied the pattern of drug resistance mutations among 138 Indian patients who experienced failure of nonnucleotide reverse-transcriptase-containing first-line highly active antiretroviral therapy. This study demonstrates a high frequency of drug resistance mutations in human immunodeficiency virus-infected Indians who experience immunologic treatment failure and suggests the need for viral load monitoring.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: no conflicts.

Comment in

References

    1. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach—2006 revision. 2006. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. Accessed 2 August 2007.
    1. Deeks S, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004; 189:312–21. - PubMed
    1. Sabin C, Hill T, Lampe F, et al.; UK Collaborative HIV Cohort (UK CHIC) Study Group. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005; 330:695. - PMC - PubMed
    1. Phillips A, Dunn D, Sabin C, et al.; UK Collaborative Group on HIV Drug Resistance. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487–94. - PubMed
    1. Soto-Ramirez L, Tripathy S, Renjifo B, Essex M. HIV-1 pol sequences from India fit distinct subtype pattern. J Acquir Immune Defic Syndr Hum Retroviral 1996; 13:299–307. - PubMed

Publication types

Substances